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Robert A. Dineen , PhD; Ann Charlotte Laska, MD; Philippe A. Lyrer, MD; Juan Jose Egea-Guerrero , PhD;  
Michal Karlinski, PhD; Hanne Christensen, DMSci; Christine Roffe , MD; Daniel Bereczki , DSc; Serefnur Ozturk , MD;  
Jegan Thanabalan , MS; Ronan Collins, MD; Maia Beridze, MD; Alfonso Ciccone, MD; Lelia Duley , FRCOG;  
Angela Shone , BSc; Philip M. Bath, FMedSci; Nikola Sprigg, DM; the TICH-2 Investigators
BACKGROUND AND PURPOSE: Seeking consent rapidly in acute stroke trials is crucial as interventions are time sensitive. We 
explored the association between consent pathways and time to enrollment in the TICH-2 (Tranexamic Acid in Intracerebral 
Haemorrhage-2) randomized controlled trial.
METHODS: Consent was provided by patients or by a relative or an independent doctor in incapacitated patients, using a 1-stage 
(full written consent) or 2-stage (initial brief consent followed by full written consent post-randomization) approach. The 
computed tomography-to-randomization time according to consent pathways was compared using the Kruskal-Wallis test. 
Multivariable logistic regression was performed to identify variables associated with onset-to-randomization time of ≤3 hours.
RESULTS: Of 2325 patients, 817 (35%) gave self-consent using 1-stage (557; 68%) or 2-stage consent (260; 32%). For 1507 
(65%), consent was provided by a relative (1 stage, 996 [66%]; 2 stage, 323 [21%]) or a doctor (all 2-stage, 188 [12%]). 
One patient did not record prerandomization consent, with written consent obtained subsequently. The median (interquartile 
range) computed tomography-to-randomization time was 55 (38–93) minutes for doctor consent, 55 (37–95) minutes for 
2-stage patient, 69 (43–110) minutes for 2-stage relative, 75 (48–124) minutes for 1-stage patient, and 90 (56–155) 
minutes for 1-stage relative consents (P<0.001). Two-stage consent was associated with onset-to-randomization time of 
≤3 hours compared with 1-stage consent (adjusted odds ratio, 1.9 [95% CI, 1.5–2.4]). Doctor consent increased the odds 
(adjusted odds ratio, 2.3 [1.5–3.5]) while relative consent reduced the odds of randomization ≤3 hours (adjusted odds ratio, 
0.10 [0.03–0.34]) compared with patient consent. Only 2 of 771 patients (0.3%) in the 2-stage pathways withdrew consent 
when full consent was sought later. Two-stage consent process did not result in higher withdrawal rates or loss to follow-up.
CONCLUSIONS: The use of initial brief consent was associated with shorter times to enrollment, while maintaining good 
participant retention. Seeking written consent from relatives was associated with significant delays.
REGISTRATION: URL: https://www.isrctn.com; Unique identifier: ISRCTN93732214.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
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Obtaining consent in a timely manner is a major chal-lenge for investigators in hyperacute stroke trials.1,2 In these studies, the intervention has to be delivered 
in a short therapeutic time window to be effective. On the 
other hand, obtaining consent is difficult when patients 
lack capacity and no relatives or people with power of 
attorney are available to provide consent on their behalf.1,2 
The COVID-19 pandemic has further complicated the 
consent process due to physical distancing precautions. 
Furthermore, patients or their representatives may also 
be overwhelmed by the acute scenario and unable to 
comprehend the information provided or the rationale 
for taking part in a clinical trial.2 Simplifying the consent 
process by providing concise but pertinent information to 
patients and their relatives may improve and shorten time 
to recruitment in acute stroke trials.
TICH-2 (Tranexamic Acid in Intracerebral Haemor-
rhage-2) endeavored to minimize time to enrollment by 
using a 2-stage pathway, where consent was sought ini-
tially from patients or their legal representatives using a 
brief information sheet followed by a full consent after 
randomization. We aimed to explore the characteristics 
of patients enrolled using 1- and 2-stage consent, the 
acceptability, and the effects on time to randomization. 
We hypothesized that the use of brief information sheets 
would reduce time to randomization.
METHODS
Data Availability Statement
The trial data can be shared upon reasonable request to the 
corresponding author and the trial steering committee.
TICH-2 was an international prospective multicenter, double-
blind, randomized placebo-controlled trial testing the efficacy 
and safety of intravenous tranexamic acid in patients with acute 
spontaneous intracerebral hemorrhage (ICH) within 8 hours of 
symptom onset. Details of the trial were published previously.3–5 
The consent-related procedures were developed in partner-
ship with stroke survivors, some of whom were members of the 
trial steering committee. The information sheets and consent 
forms were designed according to the principles outlined in the 
Medicines for Human Use (Clinical Trials Regulations) 2004 
and European Clinical Trials Directive (EC2001/20) and based 
on templates provided by the UK Health Research Authority.6 
The consent procedures were approved by each participating 
country or center’s ethics review committee.
This analysis is reported in accordance with the 
Strengthening the Reporting of Observational Studies in 
Epidemiology statement (Supplemental Methods S1 and S2).7
Definitions
A personal legal representative is a person acting as a legal 
representative to an incapacitated patient by virtue of their rela-
tionship with the patient. A personal legal representative is usu-
ally a relative but could be a close friend who may be aware of 
the patients’ likely wishes if a relative was not available. A pro-
fessional legal representative is a doctor or nominated health 
care professional unconnected to trial who acts as a patient’s 
legal representative to provide consent. A professional legal 
representative must not be involved in the trial management, 
be an investigator or part of the trial team, or be under the 
direction of the trial investigator.8 Proxy consent is a consent 
given by a personal or professional legal representative. For 
brevity purpose in this article, personal legal representative is 
referred to as a relative and professional legal representative 
as a doctor.
Consent Pathways
The consent pathways consisted of 1-stage patient and 
relative consent, 2-stage patient and relative consent, and 
2-stage doctor consent.
One-Stage Patient Consent
In the 1-stage patient consent pathway, eligible patients were 
given the full-version patient information sheet. This was a 
4-page information sheet (2474 words; Supplemental Methods 
S3) that explained the condition, the purpose of the trial, the drug 
being studied, randomization, blinding, follow-up assessments, 
possible benefit and harm, alternative treatments, withdrawal 
from the trial, data confidentiality and governance, dissemina-
tion of trial results, and complaint procedures. Patients were 
then required to provide full written informed consent by writing 
their initials adjacent to 7 relevant statements on the consent 
form and provide a full signature, name, and date. Patients with 
capacity were required to sign the form themselves. If handwrit-
ing was not possible or legible due to arm weakness or use of 
the nondominant hand, a third person acted as a witness by 
signing the form.
One-Stage Relative Consent
For incapacitated patients, a relative was approached for 
proxy consent using the full-version legal representative 
information sheet (2668 words) and consent form with 
similar details as the full patient version detailed above 
(Supplemental Methods S4).
Two-Stage Patient Consent
When it was deemed not feasible to seek full written informed 
consent due to a short therapeutic time window, patients 
provided initial consent by signing a brief information sheet, 
followed by full written informed consent at the earliest sub-
sequent opportunity after enrollment. The brief information 
Nonstandard Abbreviations and Acronyms
ESETT  Established Status Epilepticus Treatment 
Trial
FASTEST  FVIIa for Acute Hemorrhagic Stroke 
Administered at Earliest Time Trial
ICH intracerebral hemorrhage
IST-3 Third International Stroke Trial
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sheet consisted of only one page of information (288 words; 
Supplemental Methods S5) that explained the condition (ICH), 
treatment (tranexamic acid or placebo), blinding, and that there 
would be an additional computed tomography (CT) scan after 
24 hours. The patients were required to sign only once and did 
not need to initial the statements as in full consent.
Two-Stage Relative Consent
A 2-stage process using an initial brief legal representative 
information sheet (1 page, 290 words; Supplemental Methods 
S6) with similar details as the brief patient version could be 
used in seeking consent in incapacitated patients, followed 
later by full consent.
Two-Stage Doctor Consent
When the patient lacked capacity and there was no relative 
available, an independent doctor was approached to provide 
proxy consent. The independent doctor was part of the clini-
cal team caring for the patient and should not have received 
prior trial-related training. Information relating to the trial was 
provided to the doctor, and if he/she agreed for the patient’s 
inclusion in the trial, a brief information sheet was signed. 
Subsequently, a full written informed consent was sought from 
patients or their relatives as soon as practicable. Notably, doc-
tors did not provide full consent.
The Figure describes the consent pathways in TICH-2. 
Different countries had slightly different consent pathways, ver-
sions of documents in different languages. All countries permit-
ted the 1-stage patient consent, while there were variations in 
permission to use the other consent pathways (Table 1).
We retrospectively calculated the fog index, which assesses 
readability and estimates the level of education needed to 
understand the text on the first reading.9 The fog indices of the 
brief patient and legal representative information sheets were 
7.8 and 8.0, respectively, and 11.4 and 12.3 for full patient and 
legal representative information sheet. A fog index of 8.0 indi-
cates that a 13- or 14-year old would be able to understand at 
first reading, while text with a fog index of 12.0 can be under-
stood by a 17- or 18-year old.
Outcomes
We explored the time to enrollment, defined as CT-to-
randomization time, according to different consent pathways. We 
specifically explored whether consent pathways were associated 
with onset-to-randomization time of ≤3 hours. This time window 
was chosen as a meta-analysis of over 40 000 patients with trau-
matic hemorrhage and postpartum hemorrhage suggested that 
tranexamic acid is only beneficial when given within 3 hours.10 
Furthermore, most hematoma growth occurs within 3 hours.11 We 
compared follow-up completion and withdrawal rates according 
to types of initial consent as a surrogate marker for acceptability.
Statistics
Baseline characteristics and outcomes were compared using 
χ2 tests for categorical variables and Mann-Whitney U and 
Student t tests for continuous variables as appropriate. Time to 
enrollment for different consent pathways was compared using 
χ2 tests for categorical variables and Kruskal-Wallis tests for 
medians. Multivariable logistic regression, with adjustment of 
variables with P<0.1 on univariate analysis, was performed to 
Figure. Consent process in the TICH-2 trial (Tranexamic Acid in Intracerebral Haemorrhage-2).
*Patient who lacked capacity with no relatives present was discussed with an independent doctor who acted as a professional legal representative. 
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identify factors associated with onset-to-randomization times 
of ≤3 hours. In addition, we performed sensitivity analyses 
including only countries using 2-stage consent. A P of <0.05 
was considered statistically significant, and 95% CIs are given. 
Analyses were performed using the Statistical Package for the 
Social Sciences, version 26 (IBM, Armonk, NY).
RESULTS
Two thousand three hundred twenty-five patients were 
recruited from 12 countries between March 2013 and 
September 2017. Only 817 patients (35.1%) gave self-
consent by using 1-stage (557; 24%) or 2-stage consents 
(260; 11.2%). The majority of patients (1507; 64.8%) were 
enrolled by proxy consent provided by a relative (1-stage 
consent in 996 [42.8%] and 2-stage consent in 323 
[13.9%]) or by a doctor (188; 8.1%). For 1 patient from the 
United Kingdom, written consent was not given at the time 
of randomization, and this was reported as a protocol viola-
tion; full consent was subsequently given by the patient.
Of the 771 patients who provided a brief consent ini-
tially (260 patient, 323 relative, and 188 doctor consents), 
follow-on full consent was given in all but 105 patients 
(13.6%) before hospital discharge. Reasons for not obtain-
ing follow-on consent were death (n=38), patient lacked 
capacity and no relative available (n=38), discharged 
(n=8), repatriated (n=13), no reason given (n=6; Table S1). 
Only 2 patients, for whom a relative provided initial brief 
consent, declined to give further consent and withdrew 
from the trial before discharge. A further 2 patients who 
provided follow-on full consent withdrew before the day 
90 follow-up. There was no significant difference in the 
number of patients lost to follow-up and in withdrawals at 
day 90 between the different consent pathways (Table S2).
Patients who were recruited following proxy con-
sent were older, more likely to be female, and had 
higher National Institutes of Health Stroke Scale scores 
(median, 16 versus 7), lower Glasgow Coma Scale 
scores (median, 14 versus 15), severe aphasia (42.1% 
versus 2.9%), intraventricular hemorrhage (36.2% ver-
sus 24.2%), and larger hematoma volumes (mean, 30.2 
versus 12.7 mL), but there was no significant differ-
ence in onset-to-CT time (Table 2). Patients who were 
recruited via proxy consent had more hematoma expan-
sion (30.7% versus 21.9%), higher mortality (14.5% ver-
sus 2.7%) at day 7, and more death and disability (67.6% 
versus 30.5%) at day 90.
Similarly, patients who were recruited using 2-stage 
consent were older, more likely to be female, had higher 
National Institutes of Health Stroke Scale (median, 14 ver-
sus 12), more likely to have severe aphasia (31.3% ver-
sus 26.9%), intraventricular hemorrhage (34.2% versus 
29.1%), larger hematoma volume (mean, 28.6 versus 21.7 
mL), and were more likely to be recruited in the United 
Kingdom (Table 2). Patients recruited using 2-stage con-
sent had higher mortality at day 7 (27% versus 19%) and 
more death and disability at day 90 (61.3% versus 51.3%).
Using 2-stage doctor and the 2-stage patient consent 
resulted in the shortest enrollment time (median CT-to-
randomization time, 55 minutes for both) followed by 
the 2-stage relative (69 [43–110] minutes), the 1-stage 
patient (75 [48–124] minutes), and the 1-stage relative 
consent (90 [56–155]; Kruskal-Wallis test P<0.001; 
Table 3). The onset-to-treatment time was shortest with 
the 2-stage doctor consent (200 [149–259] minutes) 
compared with 267 (193–364) minutes for the 1-stage 
relative consent (the longest time to treatment). There 
was no significant difference in time from randomization 
to treatment between the consent pathways.
Apart from consent pathways, other factors associated 
with an onset-to-randomization time of ≤3 hours include 
higher National Institutes of Health Stroke Scale, higher 
Table 1. Types of Initial Consent in Each Country
 












United Kingdom* 1910 410 (21.5%) 245 (12.8%) 797 (41.7%) 313 (16.5%) 144 (7.5%)
Ireland 17 3 (17.6%) 4 (23.5%) 6 (35.3%) 4 (23.5%) 0 (0%)
Italy 96 70 (72.9%) 9 (9.4%) 13 (13.5%) 1 (1.0%) 3 (3.1%)
Switzerland 46 25 (54.3%) 0 (0%) 12 (26.1%) 0 (0%) 9 (19.6%)
Turkey 9 1 (11.1%) 0 (0%) 7 (77.8%) 1 (11.1%) NP
Malaysia 46 18 (39.1%) 0 (0%) 24 (52.2%) 4 (8.7%) NP
Spain 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) NP
Georgia 141 14 (9.9%) NP 125 (88.7%) NP 2 (1.4%)
Denmark 39 6 (15.4%) NP 3 (7.7%) NP 30 (76.9%)
Hungary 9 1 (11.1%) NP 8 (88.9%) NP NP
Sweden 8 6 (75%) 2 (25%) NP NP NP
Poland 3 3 (100%) NP NP NP NP
NP indicates not permitted in the specified country.
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systolic blood pressure, shorter onset-to-CT time, and 
recruitment from the United Kingdom (Table S3). Multi-
variable logistic regression showed that factors indepen-
dently associated with onset-to-randomization time of ≤3 
hours include higher National Institutes of Health Stroke 
Scale, higher SBP, shorter onset-to-CT time, recruitment 
from the United Kingdom, and use of 2-stage patient and 
relative consent (adjusted odds ratio, 1.89 [95% CI, 1.49–
2.39]; P<0.001; Table 4, model 1) and 2-stage doctor 
consent (adjusted odds ratio, 2.29 [1.52–3.47]; P<0.001; 
Table 4, model 2). Conversely, relative consent reduced the 
odds ratio of randomization ≤3 hours of onset (adjusted 
odds ratio, 0.10 [95% CI, 0.03–0.34]; P<0.001; Table 4, 
model 3). Sensitivity analysis excluding countries that did 
not recruit participants using 2-stage consent (Spain and 
Hungary, n=10) yielded similar results (Table S4).
DISCUSSION
In this post hoc analysis, we found that 2-stage consent 
using brief information sheets reduced the time to ran-
domization by ≈20 minutes. CT-to-randomization time was 
the shortest with the 2-stage doctor or patient consent 
and longest for consent given by relatives. Apart from 
shortening onset-to-CT time with improvement of local 
stroke pathways, the use of the rapid consent pathway 
may be one of the most important approaches to improv-
ing time to enrollment for trials of treatments for acute 
ICH, as well as more generally in all acute stroke trials.
The brief information sheet, developed in consulta-
tion with our patient, carer, and public representatives, 
was concise but contained pertinent information, which 
allowed patients to decide to proceed with the trial while 
more information was given later. The shorter text and 
better readability reduced reading time and enabled 
easier understanding. In addition, time used to sign the 
consent form was shortened with the brief consent, as 
only one signature was required instead of 7 sets of ini-
tials and one signature in the full consent. Our approach 
in developing and utilizing brief information sheet was 
similar to those that had been used in other large clinical 
trials such as IST-3 (Third International Stroke Trial).12
Most importantly, the use of brief consent appeared 
acceptable to patients and relatives, as few (2 of 771; 
0.3%) withdrew their consent when full consent was 
requested later. The use of brief consent did not result 
in higher withdrawal rates from trial or loss to follow-up. 
The Cord Pilot study, which used a similar 2-stage brief 
Table 2. Characteristics and Outcome of Patients According to Consent Type
Baseline variable Self-consent Proxy consent P value 1 stage 2 stage P value
Patients randomized 817 (35.1%) 1507 (64.8%) … 1553 (66.8%) 771 (33.2%) …
Age, y 66.23 (13.39) 70.34 (13.83) <0.001 68.5 (13.7) 69.8 (13.9) 0.027
Sex (male) 523 (64.0%) 778 (51.6%) <0.001 902 (58.1%) 399 (51.8%) 0.004
Prestroke modified Rankin Scale (/5) 0.0 (0.0–0.0) 0.0 (0.0–1.0) <0.001 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.16
Prior antiplatelet therapy 180 (22.0%) 431 (28.6%) 0.001 403 (25.9%) 208 (27.0%) 0.58
Glasgow coma scale (/15) 15 (15–15) 14 (11–15) <0.001 15 (12–15) 14 (12–15) 0.27
NIHSS score (/42) 7.0 (4.0–11.0) 16.0 (10.0–21.0) <0.001 12.0 (6.0–18.0) 14.0 (8.0–20.0) <0.001
 No aphasia 706 (86.4%) 619 (41.1%) <0.001 909 (58.5%) 416 (54.0%) 0.036
 Aphasia: mild to moderate 87 (10.6%) 254 (16.9%) <0.001 227 (14.6%) 114 (14.8%) 0.91
 Aphasia: severe or mute 24 (2.9%) 634 (42.1%) <0.001 417 (26.9%) 241 (31.3%) 0.026
 Right-sided limb weakness 273 (33.4%) 891 (59.1%) <0.001 775 (49.9%) 389 (50.5%) 0.80
Systolic blood pressure, mm Hg 175.6 (30.2) 174.4 (29.6) 0.36 173.4 (29.2) 177.6 (30.8) 0.001
Hematoma volume, mL 12.7 (15.7) 30.2 (30.0) <0.001 21.7 (25.6) 28.6 (29.6) <0.001
Intraventricular hemorrhage 167 (20.7%) 540 (36.3%) <0.001 445 (29.1%) 262 (34.2%) 0.012
Onset-to-CT time, min 118 (85–180) 114 (80–168) 0.054 116 (83–171) 112 (80–170) 0.27
UK sites 655 (80.2%) 1254 (83.2%) 0.068 1207 (77.7%) 702 (91.1%) <0.001
Hematoma expansion 168 (21.9%) 402 (30.7%) <0.001 371 (26.6%) 199 (29.2%) 0.21
Outcomes: day 7
 Do not attempt resuscitation 56 (6.5%) 453 (30.1%) <0.001 286 (18.5%) 223 (29.1%) <0.001
 Death 20 (2.4%) 204 (13.5%) <0.001 122 (7.9%) 102 (13.2%) <0.001
Day 90
 Death 69 (8.5%) 430 (28.7%) <0.001 293 (19.0%) 206 (27.0%) <0.001
 Modified Rankin Scale score 4–6 247 (30.5%) 1012 (67.6%) <0.001 792 (51.3%) 467 (61.3%) <0.001
Data are n (%), mean (SD), or median (interquartile range). Analyses are χ2 test for categorical variables, Mann-Whitney U test for median, and Student t test for mean 
comparison. One-stage consent includes 1-stage patient and relative consent. Two-stage consents include 2-stage patient, relative, and doctor consent. Proxy consent 
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consent, reported positive feedback with participants 
satisfied with the information received while having suf-
ficient time to make their decision.13 Brief consent was 
also acceptable to clinicians seeking consent.14
It is also noteworthy that a larger proportion of 
patients recruited via 2-stage process were female com-
pared with 1-stage process. While the reasons for this 
are not known and need to be further explored, the use 
of 2-stage consent could potentially improve the enroll-
ment of female participants, who are frequently under-
represented in acute stroke trials.15
Similar to previous reports,16,17 patients recruited via 
proxy consent were older, had more severe strokes, and 
would have been excluded from the trial if legal repre-
sentatives’ consent had not been permitted. Exclusion of 
incapacitated patients does not only unfairly deprive such 
patients from receiving potentially beneficial treatment but 
it also introduces selection bias, as only patients with milder 
stroke can be recruited. In this respect, the option to include 
doctors as a professional legal representatives enabled 
patients who lacked capacity to participate in the trial when 
no relatives were available. Prior knowledge of the natural 
history of ICH and the risks and benefits of tranexamic acid 
combined with the use of an initial brief consent enabled 
professional legal representative to make enrollment deci-
sions rapidly on behalf of incapacitated patients. However, 
it needs to be noted that this consent pathway was not 
permitted in all participating countries.
Proxy consent by a relative was associated with sig-
nificant delays and markedly reduced odds of randomiza-
tion within 3 hours of onset compared with self-consent. 
This supports previous findings that relatives might not 
always be suitable surrogate decision makers.18,19 Fur-
thermore, relatives may not be physically present at the 
bedside, especially in the COVID-19 era,20 and addi-
tional time is spent looking for the relatives in a busy 
emergency department. The use of digital technology 
via telemedicine, videotelephony, and electronic forms to 
seek consent from relatives may be an alternative to con-
ventional face-to-face consultations.21–23 However, the 
patient’s relatives may be stressed and distracted and 
need more time to consider their decisions or may be 
unable to make decisions.2,18,24 Results of a focus group 
consultation suggest that stroke survivors are worried 
about the additional stress the consent process imposes 
on an already distressed relative.25












Onset-to-CT time, min 115 (81–171) 99 (70–150) 117 (80–173) 119 (85–175) 119 (85–182) 116 (80–168) 0.003
CT to randomization, min 75 (47–128) 55 (38–93) 55 (37–95) 69 (43–110) 75 (48–124) 90 (56–155) <0.001
Randomization to first dose of IMP, min 20 (12–31) 17 (10–28) 18 (11–28) 19 (11–28) 18 (11–30) 22 (13–36) 0.614
Onset to randomization, min; mean (SD) 237 (102) 195 (89) 215 (98) 225 (91) 238 (108) 253 (103) <0.001
Onset to randomization, min; median (IQR) 217 (155–302) 174 (122–236) 193 (142–270) 211 (156–278) 222 (155–305) 236 (167–332) <0.001
 ≤60 2 (0.1%) 2 (1.1%) 0 0 0 0 …
 ≤120 232 (10.0%) 40 (21.3%) 41 (15.8%) 35 (10.8%) 59 (10.6%) 57 (5.7%) <0.001
 ≤180 833 (35.8%) 100 (53.2%) 114 (43.8%) 129 (39.9%) 186 (33.4%) 303 (30.4%) <0.001
Onset to first dose of IMP, min 244 (180–330) 200 (149–259) 215 (163–299) 229 (175–304) 247 (180–330) 267 (193–364) <0.001
Data are n (%), median (IQR), or mean (SD). Analyses are χ2 test for categorical variables and Kruskal-Wallis test for median or 1-way ANOVA for mean comparison. 
CT indicates computed tomography; IMP, investigational medicinal product; and IQR, interquartile range.
Table 4. Multivariable Logistic Regression of Factors Associated With Time to Randomization of ≤3 h
Variables Model 1, aOR (95% CI) P value Model 2, aOR (95% CI) P value Model 3, aOR (95% CI) P value
Age, y 1.01 (0.99–1.01) 0.26 1.01 (0.99–1.02) 0.25 1.00 (0.98–1.01) 0.55
Sex (male) 1.23 (0.98–1.54) 0.074 1.22 (0.94–1.59) 0.14 1.11 (0.88–1.40) 0.39
Systolic BP, mm Hg 1.01 (1.00–1.01) 0.001 1.01 (1.00–1.01) <0.001 1.01 (1.00–1.01) 0.001
NIHSS (/42) 1.02 (1.00–1.03) 0.046 1.02 (1.00–1.04) 0.050 1.04 (1.02–1.06) <0.001
Onset-to-CT time, min 0.97 (0.96–0.97) <0.001 0.97 (0.96–0.97) <0.001 0.97 (0.96–0.97) <0.001
Recruitment from the United Kingdom 2.68 (1.97–3.65) <0.001 3.10 (2.24–4.31) <0.001 3.29 (2.37–4.58) <0.001
Consent type*
 2-stage vs 1-stage (reference) 1.89 (1.49–2.39) <0.001 …  … …
 Doctor vs self (reference) … … 2.29 (1.52–3.47) <0.001 … …
 Relative vs self (reference) … … … … 0.10 (0.03–0.34) <0.001
aOR indicates adjusted odds ratio; BP, blood pressure; CT, computed tomography; and NIHSS, National Institutes of Health Stroke Scale.
*Three different models used as there was overlap of consent types: 1-stage consent includes 1-stage patient and relative consent; 2-stage consents include 2-stage 
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Uncertainties about the patient’s wishes, the complex-
ities of the patient’s condition and intervention, and the 
use medical terminology may lead to relatives requiring 
longer time for consent.26,27 Although it was reassuring 
that only 2 patients in this study who regained capac-
ity disagreed with their relatives’ decision and withdrew 
consent, it remains unclear how much time should be 
allowed for the consent process in an emergency setting 
and how much information should be provided.
Current European Union regulations, approved in 2014 
after the initiation of the TICH-2 trial, allow recruitment of 
patients in emergency clinical trials without prior consent, 
if the patient lacks capacity, and it is not possible to obtain 
informed consent from a legal representative within the 
therapeutic window.28 This directive defined the concept 
that expert clinicians and ethics committee, based on rig-
orous review of study protocol, are in a better position to 
make decisions on whether the trial was designed to the 
patient’s best interest.29 Furthermore, community consul-
tation during the ethics review process ensures opinions 
and concerns of the study population are taken into con-
sideration.22 While deferral or waiver of consent is permis-
sible in emergency situations and may be a preferable 
option, many researchers do not utilize this approach. A 
deferral or waiver of consent was also recommended by 
the Hemorrhagic Stroke Academia Industry Roundtable 
and the European Stroke Organisation Trials Network 
Committee as one approach of reduce time to treatment 
in stroke trials.21,30 Such deferral or waiver of consent can 
be appropriate when the condition studied is acute, rap-
idly deteriorating, with poor outcome, and the intervention 
studied has good safety profile.22 Some trialists suggest 
that seeking consent is unethical if it delays the initiation 
of trial treatment leading to reduced treatment effects. This 
is especially so if the trial intervention constitutes the only 
possibility for an improved outcome.22,31,32 Waiver of con-
sent has been successfully applied in several emergency 
trials, such as FASTEST (FVIIa for Acute Hemorrhagic 
Stroke Administered at Earliest Time Trial; https://www.
clinicaltrials.gov; unique identifier: NCT03496883) and 
ESETT (Established Status Epilepticus Treatment Trial).33
One limitation of this study is that we have not surveyed 
patients, relatives, or doctors regarding the consent pro-
cess. Future trials could explore the implications of 2-stage 
consent on participants’ experience, including if they felt 
that they were appropriately involved, the quality of interac-
tion with researchers, what they felt was important at the 
time of decision-making, their perception, understanding of 
their contribution to research as study participants, recall 
of the consent process at a later date, and postenrollment 
discussion. Although withdrawal after initial brief consent 
was rare, we have not captured data of potentially eligible 
patients who declined participation when first approached. 
As TICH-2 had a short enrollment period of only 8 hours, it 
is uncertain whether a 2-stage consent is appropriate and 
effective for trials with longer recruitment windows. Doctor 
consent was only used in a minority (8%) of patients despite 
a shorter time to enrollment. As it was not a requirement 
to appoint professional legal representative a priori, it may 
be difficult to establish in an emergency whether a doctor 
is truly unconnected to the trial. Brief and doctor consents 
were not permitted in some countries due to regulatory 
requirements, limiting the generalizability of their use.
CONCLUSIONS
In conclusion, offering a 2-stage consent process and 
engaging doctors as professional legal representatives 
should be considered in emergency stroke trials with tight 
recruitment time windows. Both processes appeared 
acceptable with good follow-up completion and the pos-
sibility to recruit more patients with severe ICH.
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